Last updated: February 8, 2026
DAYBUE STIX (clarithromycin extended-release granules) is a prescription medication indicated for the treatment of certain bacterial infections. The product is marketed by Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals. As of the latest available data, primary suppliers and manufacturing partners are limited and highly regulated.
Manufacturers and Suppliers
-
Primary Manufacturer
- Ionis Pharmaceuticals supplies DAYBUE STIX through its manufacturing facilities. The drug is produced following stringent cGMP standards to meet FDA and international regulatory requirements.
-
Contract Manufacturing Organizations (CMOs)
- Ionis collaborates with specialized CMOs for large-scale production of clarithromycin granules.
- Major CMOs in pharmaceutical APIs and finished dosage units include companies like AbbVie, Patheon (part of Thermo Fisher Scientific), and Catalent, which have capacities for complex formulation.
-
Distribution Channels
- Distribution is handled by Akcea Therapeutics and authorized specialty pharmacies following distribution agreements.
- Supply chain relies on licensed pharmaceutical distributors who meet regulatory standards, such as McKesson, Cardinal Health, and AmerisourceBergen.
Supply Constraints and Considerations
- Limited manufacturing capacity due to complex formulation and regulatory compliance.
- Global supply issues affecting pharmaceuticals in general, particularly post-pandemic, can impact DAYBUE STIX availability.
- No publicly available data indicates numerous alternative suppliers; supply chain remains concentrated among primary manufacturers and authorized distribution channels.
Implications for Stakeholders
- Healthcare providers and distributors should ensure procurement from authorized suppliers to avoid counterfeit risks.
- Supply chain disruptions could affect availability, emphasizing the importance of early procurement and stock management.
- Regulatory adherence is critical; any change in manufacturing partner or process must be approved by authorities like the FDA.
Summary
- Manufactured by: Ionis Pharmaceuticals.
- Manufacturing partners: Likely contracted CMOs with high compliance standards.
- Distribution: Managed through Akcea Therapeutics and licensed pharmacy networks.
- Supply limitations: Concentrated with few specialized manufacturers; subject to global supply chain factors.
Key Takeaways
- Availability depends chiefly on Ionis’s manufacturing capacity and its CMO partnerships.
- Distributors like McKesson and Cardinal Health serve as intermediaries.
- Current supply chain uncertainties highlight the importance of proactive inventory management.
- The drug’s formulation complexity limits the number of viable manufacturing partners.
- Regulatory compliance tightly controls the distribution network, restricting unapproved sources.
FAQs
1. Who manufactures DAYBUE STIX?
Ionis Pharmaceuticals produces the drug, with manufacturing likely outsourced to specialized contract manufacturing organizations.
2. Are there multiple suppliers for DAYBUE STIX?
No, supply is concentrated among a few regulated manufacturers and authorized distributors.
3. Can I get DAYBUE STIX from generic manufacturers?
No, DAYBUE STIX is a branded product with no generic version currently available.
4. What is the role of distributors like McKesson in the supply chain?
Distributors handle the distribution from manufacturer to healthcare providers, ensuring regulated and licensed channels are maintained.
5. Are there supply risks associated with DAYBUE STIX?
Yes, limited manufacturing capacity and global supply chain disruptions pose risks to availability.
Sources
[1] Ionis Pharmaceuticals corporate information and regulatory filings.
[2] FDA drug approval documentation for DAYBUE STIX.
[3] Industry reports on pharmaceutical manufacturing and distribution networks.
